13F filer · CIK 1844645
Pivotal bioVenture Partners Investment Advisor LLC
SAN FRANCISCO, CA · filing since Q4 2020 · last filing Aug 13, 2026
Reported value
$307.8M
+$28.0M vs prior
Positions
13
New / sold out
1 / 1
Added / reduced
3 / 4
Turnover
2.6%
buys $41.0M · sells $7.5M
Top-10 weight
95.1%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | AVALYN PHARMACEUTICALS INC | +966,792 | – | +$31.8M |
| Added | TREVI THERAPEUTICS INC | +188,946 | +12.2% | +$3.5M |
| Added | VAXCYTE INC | +53,045 | +3.9% | +$3.1M |
| Added | AVALO THERAPEUTICS INC | +138,100 | +46.7% | +$2.6M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | ZENAS BIOPHARMA INC | -101,225 | -17.1% | $-2.6M |
| Reduced | OCULIS HOLDING AG | -174,033 | -10.4% | $-2.4M |
| Reduced | ARCUTIS BIOTHERAPEUTICS INC | -90,609 | -6.7% | $-2.4M |
| Sold out | BOLT BIOTHERAPEUTICS INC | -42,581 | -100.0% | $-172.0K |
| Reduced | MAPLIGHT THERAPEUTICS INC | -1 | -0.0% | $-36 |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | VAXCYTE INCCOM | 1,425,470 | $82.9M | 26.92% |
| 2 | ARCUTIS BIOTHERAPEUTICS INCCOM | 1,265,283 | $33.2M | 10.78% |
| 3 | TREVI THERAPEUTICS INCCOM | 1,742,672 | $32.5M | 10.56% |
| 4 | AVALYN PHARMACEUTICALS INCCOM SHS | 966,792 | $31.8M | 10.34% |
| 5 | EVOMMUNE INCCOM SHS | 1,926,943 | $25.6M | 8.32% |
| 6 | MAPLIGHT THERAPEUTICS INCCOM | 611,446 | $21.9M | 7.12% |
| 7 | OCULIS HOLDING AGORDINARY SHARES | 1,506,250 | $20.9M | 6.79% |
| 8 | BIOAGE LABS INCCOM | 653,374 | $16.0M | 5.20% |
| 9 | IMMUNOME INCCOM | 732,512 | $15.5M | 5.04% |
| 10 | ZENAS BIOPHARMA INCCOM | 490,766 | $12.5M | 4.05% |
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.